About
Immune Therapies
Areas of Focus
Categories
Biologics & BiopharmaceuticalVirginia, DC, DE & Maryland
Clinical Trials (10)
View allTotal Trials
10
As Lead Sponsor
8
As Collaborator
2
Total Enrollment
1,058
By Phase
PHASE2: 2PHASE1: 3PHASE1/PHASE2: 5
By Status
RECRUITING: 3TERMINATED: 3ACTIVE_NOT_RECRUITING: 2WITHDRAWN: 1COMPLETED: 1
Clinical Trials Pipeline10 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Today
Hover over trial bars to see details
Recent Trials
NCT06941857Collaborator
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
PHASE2Recruiting
20 participants
Started: Sep 4, 2025 · Completed: Sep 30, 2030
NCT06792552Lead Sponsor
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
PHASE1Recruiting
414 participants
Started: Feb 26, 2025 · Completed: Aug 31, 2028
NCT06774963Lead Sponsor
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
PHASE1Recruiting
145 participants
Started: Jan 7, 2025 · Completed: Dec 31, 2026
NCT05787496Lead Sponsor
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
PHASE1Terminated
28 participants
Started: Feb 28, 2023 · Completed: Jan 31, 2025
NCT05572684Lead Sponsor
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors
PHASE1/PHASE2Active, not recruiting
97 participants
Started: Oct 6, 2022 · Completed: Nov 30, 2025
Locations (1)
Headquarters
Beltsville, MD, United States
Map
Loading map...